Search results
Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023
GuruFocus.com via Yahoo Singapore Finance· 4 months agoCash Position: $624 million in cash, cash equivalents, and marketable securities as of December 31, 2023. Collaboration Revenue: Increased to $5.1 million for Q4 2023, and $11.8 million for ...
Verve Therapeutics, Inc. (NASDAQ:VERV) is a favorite amongst institutional investors who own 64%
Simply Wall St. via Yahoo Singapore Finance· 5 months agoKey Insights Institutions' substantial holdings in Verve Therapeutics implies that they have...